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 INTRODUCTION 
 Malaria continues to kill and debilitate millions of people, 
despite the availability of effective drugs. Delayed treatment 
caused by its rather non-specific symptoms and rapid onset of 
severe disease is the main reason for this mortality, but there 
is increasing realization that drug resistance may play a major 
role. The gold-standard surveillance technique for detect-
ing drug resistance is direct observation  in vivo ; patients are 
treated, and success or failure is observed. This approach is 
logistically difficult, because it requires extended follow-up 
periods that are difficult to achieve and consequently, sample 
sizes are small. An alternative approach is to monitor muta-
tions associated with drug resistance. 1 These can be readily 
detected in the parasites contained in infected human blood 
samples, which are relatively easy and economical to collect 
and can be rapidly screened. These single nucleotide poly-
morphisms (SNPs) or molecular markers of drug resistance, 
therefore, have the potential to guide public-health policy in 
a timely manner. 2, 3 Importantly, the optimal way of analyz-
ing these data has never been fully explored, and therefore, it 
remains a subject of intense debate, particularly for samples 
originating from the areas of intense malaria transmission 
that characterize much of sub-Saharan Africa; these areas are 
where most malaria mortality occurs and where the need for 
informed drug policy choice is greatest. This manuscript con-
siders the appropriate methods of analyzing and presenting 
molecular marker data from such areas by evaluating alterna-
tive methods of analysis. 
 A major problem in analyzing human blood samples is that 
humans in areas of moderate to high malaria transmission are 
often infected by several genetically distinct malaria clones; 
the number of clones is known as their multiplicity of infec-
tion (MOI). Consequently, many blood samples will have 
MOI > 1 and be genetically ambiguous; for example, if a sam-
ple has a MOI of 4 and is known to contain both wild-type 
and mutant SNPs, it is impossible to discern whether the ratio 
of wild-type to mutant clones in the sample is 3:1, 2:2, or 1:3. 
A second problem is that relatively low assay sensitivity 
seems to be an inherent property of polymerase chain reac-
tion (PCR)-based genotyping methodology. Liu and others 4 
found it difficult to detect minor SNPs if they were present 
in less than around 10% of the parasites in the sample, even 
under idealized laboratory conditions, whereas Juliano and 
others 5 assert, more realistically in our view, that the detec-
tion limit in most protocols is closer to 20%; there is also 
likely to be substantial variation in assay sensitivity between 
different laboratories. 6 These inherent methodological lim-
its are often augmented by assay protocol steps designed to 
eliminate false-positive SNP signals; in the genotyping results 
that we analyze herein, this was implemented as an instruc-
tion to ignore any signal that was less than 30% of the larger 
signal. This inability to detect minor SNPs leads to misclas-
sification. For example, if MOI = 5 and contains one mutant 
clone and four wild types, then the marker will, on average 
(see Discussion), constitute around 1/5 (20%) of the total 
DNA and may be missed; this leads to the sample being incor-
rectly classified as containing only wild-type markers. The 
appropriate genotyping sensitivity limit (GSL) needs to be 
incorporated into analyses of human blood data in areas of 
high MOI. 
 Despite the interest in using molecular markers to guide 
policy, 1– 3 there has been relatively little discussion about the 
most appropriate way to analyze human blood samples in 
the context of genetic ambiguity caused by high MOI and 
misclassification caused by low assay sensitivity. This man-
uscript addresses these issues. We first consider the impli-
cations of summarizing data by prevalence rather than 
frequency. Second, we critically evaluate four potential meth-
ods of estimating frequency. Third, we show the importance 
of allowing for assay sensitivity, quantified at its GSL, in 
analyses. 
 MATERIALS AND METHODS 
 Prevalence is defined as the proportion of human blood sam-
ples where the marker is present, implying that one or more 
clones in the sample carry the marker. Frequency is defined 
as the proportion of individual malaria clones that carries the 
marker. The theoretical relationship between the prevalence 
of markers and underlying mutation frequency depends on 
the distribution of MOI as follows:
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where  n is MOI,  n_ max is maximum observed MOI,  f ( n ) is 
the frequency of samples with MOI =  n , and  p is the frequency 
of the mutation. This assumes perfect detection of mutations. 
If minor clones are missed (i.e., a GSL occurred), it is neces-
sary to consider each SNP combination within each MOI class 
to test whether its presence would be detected. This is done 
using the binomial distribution as follows:
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where  c is the number of mutant clones within the  n clones 
of the sample and  v is an indicator variable that takes a value 
of zero if  c/n is less than the GSL and unity if  c/n is equal or 
greater than the GSL. 
 We analyzed two real field datasets, one from a relatively 
low-transmission area of Papua New Guinea (PNG) and one 
from a high-transmission area of Tanzania; both were geno-
typed by the same person using the same protocol in the same 
laboratory. The PNG samples 7 were obtained from patients 
(of all ages) attending the health center in the Wosera area 
during 2000 and 2001 with presumptive symptoms of malaria. 
Blood was collected by venipuncture or fingerprick into eth-
ylenediaminetetraacetic acid (EDTA) microtainers and glass 
capillaries, respectively, and stored at −70°C. This dataset con-
sisted of 100 malaria-infected blood samples containing a total 
of 173 clones. The Tanzanian samples were collected from the 
placebo group (ages 1–5 years) of the Spf66 vaccine trial 8 
in the Morogoro region of Tanzania during 1993 and 1994. 7 
Blood samples were collected by fingerprick into heparinized 
microtainers and stored at −70°C. This dataset consisted of 
82 malaria-infected blood samples containing a total of 298 
clones. DNA was extracted, and the parasites were genotyped 
at merozoites surface protein 2 (MSP2) to establish the MOI 
and at several loci implicated in drug resistance as described 
previously, 7, 9 although only two resistance loci were analyzed 
here (i.e.,  dhfr in the PNG datasets and both  dhfr and  dhps in 
the more interesting Tanzanian dataset). Genotypic failures 
(entered as missing data in the analyses) were around 3% per 
SNP. Critically, the protocol explicitly stated that any SNP sig-
nals less than 30% of the major SNP genotype were ignored; 
hence, the GSL is 0.3. We chose these datasets, because both 
were genotyped in the same laboratory by the same person 
(Nsanzabana), maximizing their comparability, and they had a 
clearly stated assay GSL. We note that our Tanzanian datasets 
had relatively high MOI, and recent malaria-control efforts 
have tended to reduce the intensity of transmission (and 
hence, MOI) in many African settings. We similarly note that 
the GSL of 30% was relatively high. The biases and errors 
noted in the main text become accentuated at high MOI and 
low assay sensitivity, and therefore, it is likely that our analysis 
represents a near worst-case scenario, although this does have 
the advantage of clearly showing the dangers and biases that 
may be encountered in these types of molecular analysis. 
 We obtained SNP and haplotype frequencies in our field 
datasets using four methods of estimation, two of which can 
also allow for a missing minor clone, giving a total of six 
methods. 
 (1)  Direct counting of SNPs and haplotypes in samples with 
MOI = 1. 
 (2)  Direct counting of SNPs in samples with MOI ≤ 2. 
Haplotypes cannot be counted in such samples, because 
they may be ambiguous. For example, if MOI = 2, the hap-
lotype is defined at two codons (e.g., 108 and 59 in  pfd-
hfr ) and the sample is mixed wild type/mutant at both 
codons: it is impossible to discern the linkage phase 10 
(i.e., whether the two constituent haplotypes are ++ with 
−− or +− with −+ (where + represents the mutation and – 
represents the wild type). 
 (3)  Direct counting of SNPs and haplotypes in unambiguous 
samples. Obviously, not all blood samples are ambigu-
ous. For example, if MOI is 4 and contains only wild-type 
markers, then we can directly count four wild-type clones; 
similarly, if MOI is 2 and contains only mutants at two 
SNPs, then we can directly count two ++ haplotypes. These 
unambiguous samples allow simple counting, even when 
MOI > 2. 
 (4)  Direct counting of SNPs and haplotypes in unambiguous 
samples allowing for GSL. Samples where, in principle, 
one SNP may be present but not detected are classed as 
ambiguous and ignored. For example, if MOI is 4 and the 
GSL is 30%, then any samples with MOI ≥ 4 should be 
ignored, because if the SNP was present in only a single 
clone, its contribution would be on average 1/4 (25%; see 
Discussion), which is less than 30% and may not be 
detected. 
 (5)  Maximum likelihood (ML) estimation of SNPs and haplo-
types frequencies, assuming that all clones are detected. 
 (6)  ML estimation of SNPs and haplotypes frequencies allow-
ing for GSL. 
 An revised version of MalHaploFreq 11 was written to 
incorporate all methods of analysis (i.e., MOI = 1, MOI = 2, 
unambiguous samples, and ML). This version (v2.1) is freely 
available for download at  http://pcwww.liv.ac.uk/hastings/
MalHaploFreq ; 95% confidence intervals (CI) around the fre-
quency estimates obtained by all methods, including counting, 
were obtained by maximum likelihood, where the CI limits 
are defined as 2 log units less than the maximum log likeli-
hood. This may lead to underestimates of the width of CI when 
frequencies are close to 0% or 100% 12 but allows for direct 
comparison across analyses using different methods and dif-
ferent frequency estimates. MalHaploFreq outputs the SNP 
and haplotype counts (and their denominators) so that users 
can, if they wish, generate their own CI around count data, 
using methods described elsewhere. 12 
 MalHaploFreq was run with level of precision set to 8 for 
frequency estimation and 3 for generation of CIs. The GSL, 
where invoked, was set at 30%. Haplotype frequencies for 
 pfdhfr were estimated using MalHaploFreq option 4, which 
assumes that the following three haplotypes do not exist:  pfd-
hfr 51 mutant alone,  pfdhfr 59 mutant alone, and the double 
mutant haplotype  pfdhfr 51 mutant +  pfdhfr 59 mutant. 
 The internal simulation facility in MalHaploFreq was 
invoked to investigate how GSL affects the width of the CIs 
around frequency estimates. Artificial datasets, each of 100 
individuals with MOI frequencies observed in Tanzania, were 
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generated, assuming GSL of 0.0, 0.1. 0.2, 0.3, and 0.4. Five arti-
ficial datasets were analyzed, and the mean width of the CI 
was recorded. 
 The assumptions inherent in this and similar ML analyses 
have been described elsewhere, 11, 13, 14 but we include them in 
Appendix S1 in the interest of transparency. It has also become 
clear that this ML technique is unfamiliar to a substantial pro-
portion of readers, and therefore we add points of clarification 
in Appendix S1. 
 Prevalences of SNPs and multilocus genotypes in the PNG 
and Tanzanian datasets were obtained by direct counting and 
95% CIs around these proportions obtained using the Wald 
method from the GraphPad website ( http://www.graphpad.
com/quickcalcs/ConfInterval1.cfm ). Note that prevalences 
do not sum to 100%, because many samples are ambiguous 
(e.g., a sample containing both wild-type and mutant SNPs will 
be counted two times, one time in counting the prevalence of 
the wild type and one time in counting the prevalence of the 
mutation). Similarly, if a sample is mixed at two loci, it will be 
included in four multilocus counts: −−, −+, +−, and ++ where − 
represents wild type and + represents the mutation; note that 
the linkage phase is not considered in this counting, and there-
fore, the estimates of multilocus genotype prevalence should 
not be confused with prevalence of haplotypes. 
 RESULTS 
 The two study sites showed very different distributions of 
MOI ( Figure 1 ), with the Tanzania dataset having much higher 
MOI. These observed MOI distributions were used to inves-
tigate the theoretical relationship between prevalence and 
mutation frequency in the two sites. As expected, predicted 
prevalence differed substantially between the two sites, even 
when resistance was present at the same frequency ( Figure 1C ) 
because of their differing MOIs (Equations 1 and 2). 
Importantly, the presence of a GSL meant that observed prev-
alence should theoretically be substantially lower than true 
prevalence ( Figure 1C ) in the Tanzanian dataset. 
 The results of SNP and haplotype frequency estimates from 
field data from PNG were fairly consistent between the dif-
ferent analyses ( Table 1 ). For SNP frequency estimation, 
there were 45 clones among the samples with MOI = 1, and 
117 clones in the samples with MOI ≤ 2, whereas ML analy-
sis included ~170 clones in the analyses and the width of the 
CIs fell as more clones entered the analysis. It is not possi-
ble to use the MOI ≤ 2 approach in haplotype analysis (see 
Materials and Methods), and therefore, the choice was between 
MOI = 1 (45 clones) and ML analysis (167 clones), with the 
latter giving smaller CIs. Interestingly, there was a discrep-
ancy in the  dhfr −+ frequency estimates: it was 0.022 by direct 
counting in MOI = 1 class and around 0.1 in other methods; we 
are unable to explain this other than purely because of chance. 
Incorporating the GSL gave a significantly better fit to the 
data in both SNP and haplotype analyses ( Table 1 ) (a 2-unit 
change in log likelihood (LL) is conventionally regarded as 
statistically significant), although it made no appreciable dif-
ference to the frequency estimates or their associated CIs. 
 The results from the Tanzania field dataset differed greatly 
between the six methods of analysis ( Table 1 ). Direct counting 
when MOI = 1 only allowed three clones to enter the analy-
ses, was uninformative. Counting SNPs in samples where MOI 
≤ 2 increased sample size from 3 to > 60 ( Table 1 ), but the 
CIs were wider than subsequent analyses and this approach 
could not be used to count haplotypes. Unambiguous samples 
assuming no GSL allowed a large number of clones to enter 
the analysis (200 + in SNP analysis), although this number fell 
dramatically when a GSL was recognized because all samples 
with MOI ≥ 4 were then excluded (because one minor clone 
among four could be present at < 25%, which is below the GSL 
of 0.3). ML analyses allowed > 260 clones to enter the analyses; 
the exact number varied depending on missing data. Allowing 
for the GSL had a large impact when SNP frequencies were 
less than around 25% (i.e., all SNPs except  dhfrS108N on 
 Table 1 ) or when haplotype frequencies were less than about 
10% ( dhfr haplotypes +−+ and +++ and all  dhps haplotypes 
except wild type on  Table 1 ). The magnitude of the effect was 
large: frequency estimates for these SNPs and haplotypes 
were consistently around 2-fold higher in analyses allowing 
for GSL. The likelihoods were substantially lower for analy-
ses that allowed a GSL, indicating that these estimates pro-
vided a far better fit to the data. This shows that not allowing 
for a GSL leads to a 2-fold error in estimating SNPs and hap-
lotypes present at low frequencies. 
 Figure 1.  ( A and  B ) Observed distribution of MOI from Papua 
New Guinea (PNG) and Tanzanian datasets. ( C ) The theoretical 
relationship between prevalence and mutation frequency given the 
observed MOI; prevalence in the Tanzanian data is shown assuming 
no genotyping sensitivity limit (GSL) or assuming a GSL of 0.3. This 
figure appears in color at  www.ajtmh.org . 
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 The presence of a GSL, therefore, has a large impact on 
frequency and prevalence estimates. We further investigated 
the value of GSL in our Tanzanian datasets by systematically 
varying its assumed value in the ML analysis. The reasoning 
was that, although the nominal GSL stated in the assay pro-
tocol was 0.3, its operational value in practice may have been 
higher or lower than this value. This operational GSL value 
was obtained by varying the GSL value to find the values (its 
ML estimator) that maximizes the likelihood of observing the 
data. Illustrative results for SNPs and haplotypes are given in 
 Figure 2 . There was a limit to increasing our assumed GSL, 
because mixed wild-type + mutant samples are not compat-
ible with high GSL (clarification 5 in Supplemental Appendix 
S1, available at  www.ajtmh.org ). The likelihood increases with 
GSL, showing a better fit to data as GSL increases ( Figure 2 ). 
This implies that, at least in these surveys, the effective GSL 
may, in practice, be much larger than the nominal value of 0.3 
stated in the protocol. However, the impact on estimated fre-
quencies was small. The  dhfr allele frequency estimates did 
not alter, because the GSL could not be increased beyond 
0.33, which gave identical results to those obtained at 0.3. 
There were slight changes in estimated frequencies at dhps: 
 dhps A437G increased from 0.12 to 0.14 and  dhps K540E 
increased from 0.17 to 0.19. Among the dhps437/540 haplo-
types using + to indicate mutant, the – – haplotype frequency 
fell from 0.85 to 0.82, the +− frequency increased from 0.007 
to 0.008, the −+ frequency increased from 0.021 to 0.025, and 
the ++ frequency increased from 0.12 to 0.14. 
 A surprising observation was that prevalences directly 
observed in our high MOI Tanzanian dataset were close to our 
best estimates of frequency ( Table 1 ), despite the theoretical 
expectation that they would be much higher ( Figure 1 ). 
 The size of GSL did slightly affect the precision of fre-
quency estimates as measured by the width of CI. The effect 
was minimal when simulated frequencies were evenly distrib-
uted between 0% and 100% (results not shown). The effect of 
ambiguity introduced by increasing GSL did have an effect 
when frequencies were constrained to lie between 2% and 
10%: the mean width of CI was 5.2% units when GSL was 0 
or 0.1, rising to 5.5%, 6.7%, and 7.6% units when GSL was 0.2, 
0.3, and 0.4, respectively (standard error of these widths was 
0.06% units in each case). 
 DISCUSSION 
 It was important to clearly define the difference between 
the prevalence and frequency of markers and haplotypes (see 
Results), because there is a tendency for researchers to regard 
them as synonymous. Equations 1 and 2 and  Figure 1C clearly 
show the operational distinction: as transmission changes, so 
does MOI and consequently, so does prevalence. This occurs 
because each clone in the MOI has a chance of carrying the 
resistance marker; a useful approximation at low frequen-
cies of the marker is that prevalence ~ frequency × MOI. 
This effect of MOI makes it impossible to use prevalence to 
compare the level of resistance at different sites or perhaps 
more importantly, to assess the impact of interventions on 
drug resistance. A relatively common conclusion from stud-
ies of malaria-control intervention (e.g., bed-net provision 15, 16 
or mosquito control 17 ) is that the intervention reduces selec-
tion for resistance. The molecular components of such studies 
invariably base the pre- and post-intervention comparison on 
the prevalence of molecular markers of resistance: any effec-
tive intervention will tend to reduce MOI, and therefore, it 
will inevitably reduce prevalence, irrespective of its impact on 
frequency. The confounding factor of MOI together with other 
key features, such as immigration of sensitive malaria into the 
study sites, weaken these conclusions. Furthermore, Equation 
2 and  Figure 1C shows that, in areas of high transmission, the 
presence of a GSL may result in observed prevalence being 
substantially lower than true prevalence; this reduces the abil-
ity to compare results from surveys performed by different 
research groups whose assay sensitivities may vary. Moreover, 
there seems to be no obvious way to incorporate GSL into 
measurements of prevalence ( Figure 1C ). Frequency esti-
mates, therefore, constitute a common scale, unaffected by 
malaria epidemiology and MOI, on which to compare levels 
of resistance. Despite these theoretical predictions, observed 
prevalences in our dataset seem relatively close to our best 
frequency estimates; the most likely reason is that the rela-
tively high GSL (see Discussion) and fluctuations in clonal 
density (Supplemental Appendix S1) mean that only one or 
two numerical dominant clones are likely to enter the SNP 
genotyping. 
 Prevalence and frequency may have different clinical impli-
cations. If the intention is to clear all parasites, then the pres-
ence of even a single resistant clone may prevent this, leading 
to parasitological failure; this would be related to prevalence. 
If symptomatic disease is associated with a single pathogenic 
clone, then clinical failure (i.e., the inability to clear the patho-
genic clone) depends on the probability that the single clone 
bears a resistance mutation(s) (i.e., on the frequency of the 
SNP or haplotype). Given the relative ease of including a 
marker of MOI in genetic analyses, the above arguments con-
stitute a compelling argument that MOI be measured and fre-
quencies calculated and reported along with any estimates of 
prevalence (although we do note that some inaccuracies may 
arise in estimating MOI; see assumption 1 in Supplemental 
Appendix S1). 
 Having established that frequency estimates of both SNPs 
and haplotypes are important, the obvious question is what 
 Figure 2.  Changes in the observed maximum log likelihood with 
the assumed value of the detection limit (GSL) in the SNP and hap-
lotype analyses on the Tanzania dataset. Increasing maximum LL 
indicates a better fit to the data. The curves have flat segments where 
changes in detection limit do not alter the likelihood, because the 
changes do not alter classification of mixed samples into all mutant 
or all wild type. Steps in the curves occur when the detection limit 
changes sufficiently to reclassify some of the mixed samples. This fig-
ure appears in color at  www.ajtmh.org . 
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is the best method to obtain these estimates? Unambiguous 
sample selection will be ignored in subsequent discussion, 
because it seems pointless to use a method that is demonstra-
bly biased (see below). In our PNG dataset with low MOI, all 
methods gave similar frequency estimates; however, the ML 
methods incorporated all the data, and so, they tended to give 
narrow CIs and did not require data selection, reducing con-
cerns about bias. These two factors suggest ML is superior to 
the other two methods, but in practice, it made little difference 
( Table 1 ). This conclusion accords with that of Anderson and 
others, 18 who found little difference between three methods of 
frequency estimation (MOI = 1, ML estimation, and predomi-
nant allele counting) in relatively low-transmissions areas of 
southeast Asia. The situation was very different in areas of high 
transmission as illustrated by the results shown on  Table 1 from 
the Tanzanian dataset: MOI = 1 analyses allowed only three 
clones to be counted, and MOI ≤ 2 could not be used for hap-
lotype counting. This left ML (or similar inference techniques 
such as Markov Chain Monte Carlo (MCMC) ; Supplemental 
Appendix S1) as the only effective method to extract fre-
quency estimates with reasonable CI from field samples. 
 The necessity of data selection in the first three methods 
(i.e., analyses restricted to MOI = 1, MOI ≤ 2, or unambig-
uous samples) immediately raises the prospect of introduc-
ing bias into the analyses. There are at least two potential 
sources of bias in the analyses restricted to MOI = 1 and MOI 
≤ 2. First, Schoepflin and others 19 noted that mutant SNP fre-
quencies may be higher in newly acquired infections and 
suggested that this may be caused by putative fitness effects 
associated with the mutations being less deleterious when 
there are no competing coinfecting clones. Second, low MOI 
infections may reflect recent drug use; most antimalarial 
drugs have long half-lives, and the first clones to recolonize 
treated individuals tend to be those that are more resistant to 
the drug, 20– 22 making resistance mutations likely to be over-
represented in infections with low MOI. An important bias 
arises in analyses counting unambiguous samples, because 
low-frequency SNPs and haplotypes will be systematically 
underrepresented. As an example, imagine a fictitious situa-
tion where all samples have an MOI = 3 and a mutant SNP is 
present at a frequency of 10%. Assuming independent acqui-
sition of clones, the probability of a sample being unambigu-
ously all mutant is 0.1 3 (i.e., 1 in 1,000). Most mutant SNPs 
will, therefore, occur in samples that also contain wild types, 
and all such samples will be excluded on the basis of ambigu-
ity. This results in underestimating the frequency of the less 
frequent SNP. The bias does not seem to be huge ( Table 1 ), 
but it is noticeable that the unambiguous samples consis-
tently gave lower frequency estimates (for low-frequency 
SNPs) and higher frequency estimates (for higher frequency 
SNPs and haplotypes) than their ML equivalent, providing 
good empirical evidence that the bias does occur in practice. 
Anderson and others 18 suggested a method of SNP frequency 
estimation based on counting the dominant allele signal in a 
sample. This is likely to be biased for the same reason as anal-
yses based on unambiguous samples: low-frequency SNPs 
are likely to be minor, non-dominant clones in high-MOI 
mixed infections (because other clones in the sample bear-
ing the alternative high-frequency SNP will combine to pro-
vide the dominant SNP signal) and therefore, will not enter 
the analysis. This leads to systematic underestimation of low-
frequency SNPs. 
 The results shown in  Table 1 show the importance of incor-
porating GSL when estimating SNP and haplotype frequen-
cies in areas with high MOIs; failure to do so may result in a 
2-fold underestimate of SNPs and haplotypes present at low 
frequency. Most surveillance surveys are explicitly designed to 
detect resistance markers as they spread from low frequen-
cies, and therefore, incorporating GSL is an important facet of 
molecular surveillance analysis. It is straightforward to incor-
porate GSL into MalHaploFreq, although this software neces-
sarily implements this in a rather crude manner (Supplemental 
Appendix S1). It is essential that researchers report their 
likely GSL in publications, because its value may vary substan-
tially; for example, GSL was 30% in our analysis, 7, 9 whereas 
Anderson and others 18 used 10%. It also seems that some lab-
oratories do not use a formal definition of what constitutes a 
minor peak and rely on individuals to make a subjective deci-
sion as to whether a minor peak represents a minor clone or 
is an artefact. In the absence of such information, we would 
tend to agree with Liu and others 4 and suggest a GSL of 20% 
in PCR-based analyses with the recommendation that values 
10%, 15%, and 25% also be tested to assess whether they pro-
vide a much better fit to the data ( Figure 2 ). This is important 
because our analyses suggest that the effective GSL may differ 
from that stated in the protocol ( Figure 2 ). The lack of assay 
sensitivity meant that true prevalence was underestimated 
to the extent that it became similar to estimated frequency 
( Figure 1C and  Table 1 ); this observation together with the 
analysis shown on  Figure 2 suggest operational assay sensitiv-
ity may be much lower than anticipated. It is ironic, given the 
limitations of prevalences (see Results), that they end up with 
similar values to frequencies. As assay sensitivity improves, it 
is inevitable that prevalence will be better estimated and that 
frequency and prevalence estimates will diverge ( Figure 1C ). 
The impact of GSL serves as an impetus driving attempts to 
increase assay sensitivity through novel protocols 23 ; in partic-
ular, it increases the precision of frequency estimates in the 
early stages of mutation spread when their frequencies are 
low. Simulations indicate that, in the Tanzanian dataset, the 
width of the CI would fall from 7.5% units to 5.2% units as 
GSL fell from 0.4 to < 0.1. 
 To summarize, we strongly urge researchers to estimate and 
report frequencies as well as prevalences: the former consti-
tutes a common scale of measurements unaffected by different 
malaria epidemiology (MOIs) and different laboratory prac-
tices (which determine GSL). Many malaria endemic areas 
have recently reported rapid reductions in transmission inten-
sity. This is reflected in reductions in MOI and hence, decreases 
in the prevalence of resistance SNPs, even when there is no 
change in the frequency of genetic resistance. Frequency esti-
mates are, therefore, essential to gauge the impact of inter-
ventions on antimalarial drug resistance. It is also important 
to present haplotype frequencies as well as individual con-
stituent SNPs, because SNPs rarely act independently and 
their combination in haplotypes is often more important than 
their individual frequencies and prevalences. 24 Researchers 
should also consider, report, and incorporate the likely GSL 
of their protocols. Here, we have attempted to describe the 
best ways to obtain good-quality, unbiased genetic data from 
surveys attempting to monitor the spread of antimalarial drug 
resistance and have updated, and provide, freely available soft-
ware to achieve this. The future success of molecular markers 
to guide antimalarial drug-deployment policy lies in providing 
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consistent, comparable, quality data on which rational deci-
sions can be based. The analyses described above constitute 
an important first step in developing and describing a frame-
work for achieving this. 
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